Drugs / IY-828026A
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07433556 Comparator | Mar 2026 → Mar 2027 expected | — | Il-Yang Pharm. Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IY-828026A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07433556 ↗ |
| Route | Oral | “Participants will receive oral administration of IY-828026A 40mg once daily for 7 days” NCT07433556 ↗ |